In Brief This Week: Danaher; ACGT, CAP; Thermo Fisher; Quest, CDC; Cleveland Clinic Labs, ACL Labs; More | GenomeWeb

NEW YORK (GenomeWeb News) – Danaher said this week that it anticipates its second-quarter diluted net earnings per share to be "slightly above" the high end of its previously announced guidance of between $.80 and $.85. Core revenue growth, it added is expected to also be "slightly above" the previous guidance of between 1 percent and 2 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.